Insider Buying: AstraZeneca PLC (LON:AZN) Insider Buys £2,360 in Stock

AstraZeneca PLC (LON:AZN) insider Michel Demare acquired 2,000 shares of the business’s stock in a transaction on Friday, September 13th. The stock was purchased at an average price of GBX 118 ($1.56) per share, for a total transaction of £2,360 ($3,117.57).

AstraZeneca Trading Up 0.7 %

Shares of LON:AZN opened at £120.16 ($158.73) on Tuesday. AstraZeneca PLC has a twelve month low of GBX 9,461 ($124.98) and a twelve month high of £133.88 ($176.86). The firm has a market cap of £186.25 billion, a P/E ratio of 3,851.28, a P/E/G ratio of 0.93 and a beta of 0.17. The company has a 50 day moving average of £125.81 and a 200-day moving average of £119.05. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97.

AstraZeneca Cuts Dividend

The company also recently declared a dividend, which was paid on Monday, September 9th. Stockholders of record on Thursday, August 8th were issued a dividend of GBX 77.60 ($1.03) per share. The ex-dividend date of this dividend was Thursday, August 8th. This represents a dividend yield of 0.64%. AstraZeneca’s dividend payout ratio is currently 7,500.00%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on AZN shares. Berenberg Bank reissued a “buy” rating and issued a £150 ($198.15) target price on shares of AstraZeneca in a research report on Monday, September 2nd. Citigroup reissued a “buy” rating on shares of AstraZeneca in a research report on Tuesday, May 28th. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Thursday, July 25th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a research report on Monday. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a £110 ($145.31) target price on shares of AstraZeneca in a research report on Tuesday, September 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and a consensus price target of £105.53 ($139.41).

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.